ERBB2 and breast cancer: The oncogene MYC is amplified in approximately 15% ofbreast cancers, it is associated with poor prognosis and correlateswith unique metabolic vulnerabilities. ErbB2/HER2 is overexpressed in 20% of human breast cancers and correlateswith tumor chemo-resistance and poor prognosis. Consistent with previous data to show that these two oncogenesare associated with distinct metabolic profiles, NN t-SNE of MSI data following background subtraction (Figure ) clearly segmentsMYC from ErbB2 tumors and NMG samples in low dimensional space (Figure a,b).